1. Home
  2. GERN vs EVLV Comparison

GERN vs EVLV Comparison

Compare GERN & EVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geron Corporation

GERN

Geron Corporation

SELL

Current Price

$1.17

Market Cap

1.0B

Sector

Health Care

ML Signal

SELL

Logo Evolv Technologies Holdings Inc.

EVLV

Evolv Technologies Holdings Inc.

SELL

Current Price

$4.16

Market Cap

994.7M

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
GERN
EVLV
Founded
1990
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
994.7M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
GERN
EVLV
Price
$1.17
$4.16
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$4.25
★ $9.85
AVG Volume (30 Days)
★ 6.8M
2.1M
Earning Date
11-04-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 51.85
41.18
EPS
★ N/A
N/A
Revenue
$1,065,000.00
★ $145,905,000.00
Revenue This Year
$28.49
$25.01
Revenue Next Year
$44.73
$20.02
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 40.48
52 Week Low
$1.04
$4.02
52 Week High
$2.01
$8.40

Technical Indicators

Market Signals
Indicator
GERN
EVLV
Relative Strength Index (RSI) 36.90 29.95
Support Level $1.08 N/A
Resistance Level $1.26 $5.86
Average True Range (ATR) 0.04 0.15
MACD 0.01 -0.03
Stochastic Oscillator 15.00 16.23

Price Performance

Historical Comparison
GERN
EVLV

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

About EVLV Evolv Technologies Holdings Inc.

Evolv Technologies Holdings Inc is a security technology company pioneering Artificial Intelligence (AI)-powered screening solutions designed to help create safer environments while maintaining efficient visitor flow and a positive visitor experience. It serves customers across a range of end markets, including education, healthcare, sports, live entertainment, tourist attractions, houses of worship, and industrial workplaces. The company operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.

Share on Social Networks: